ROIV News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RO

Mkt Cap

$24.21B

Volume

3.61M

Next Earnings

November 9th

Loading chart

RO

ROIVRoivant Sciences Ltd. Common Shares

ROIV

Pay with—

Available Balance0.00

RO

Mkt Cap

$24.59B

Volume

3.61M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Company News for Sep 9, 2026Several stocks experienced significant price movements based on recent developments. QUALCOMM rose 3.2% following a data center partnership with AWS and positive AI growth outlook. Roivant Sciences surged 18.8% after positive Phase 2 results for its pulmonary hypertension drug. Bloom Energy gained 9.6% after being added to the S&P 500. However, Novartis tumbled 13.9% after its del-desiran drug failed to meet Phase 3 trial expectations for myotonic dystrophy treatment.Zacks Investment Research · Sep 9, 2026

Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive DirectorLindus Therapeutics, a drug development company focused on in-licensed assets, has appointed Dr. Gillian Cannon as a non-executive director. Cannon brings over 30 years of biopharmaceutical commercial leadership experience from roles at Merck and Roivant Sciences. She will help shape the company's commercial strategy as it builds its portfolio of clinical-stage assets.GlobeNewswire Inc. · Sep 8, 2026

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsightThe myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.GlobeNewswire Inc. · May 18, 2026

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightThe generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, BTK inhibitors, and innovative CAR-T cell therapies from major pharmaceutical companies.GlobeNewswire Inc. · Apr 15, 2026

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)Priovant Therapeutics announced enrollment of the first subjects in a Phase 2b/3 clinical trial of brepocitinib for lichen planopilaris (LPP), marking the fourth indication in the drug's late-stage development program. The company expects a potential FDA approval for brepocitinib in dermatomyositis in Q3 2026, with additional Phase 3 data expected in non-infectious uveitis and Phase 3 initiation in cutaneous sarcoidosis in H2 2026.GlobeNewswire Inc. · Apr 2, 2026

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in DermatomyositisPriovant Therapeutics announced that its Phase 3 VALOR trial of brepocitinib 30 mg met its primary endpoint for treating dermatomyositis, showing superior efficacy to placebo across multiple measures including muscle strength, skin disease, and corticosteroid reduction. The FDA has granted Priority Review with a PDUFA target action date in Q3 2026. Serious infections were elevated in the treatment group compared to placebo, though they resolved with medical management.GlobeNewswire Inc. · Mar 28, 2026

9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside PotentialModerna settled a long-running legal dispute over COVID-19 vaccine technology, paying $2.25 billion to Roivant Sciences' Genevant unit and Arbutus Biopharma—less than the $3 billion expected. While Moderna stock surged 15.99% on the news, analysts suggest it now trades 22% above fair value after a 108% six-month rally. The article identifies 9 biotech stocks trading 27.6% to 64.6% below fair value with potential upside of 31.6% to 251.4%.Investing.com · Mar 5, 2026

Moderna's $950 Million Settlement Clears Legal Overhang, Stock SoarsModerna reached a $950 million settlement agreement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving litigation related to its COVID-19 vaccine Spikevax and mRESVIA product. The settlement clears a major legal overhang, allowing the company to focus on future growth. Moderna expects to end 2026 with $4.5-5 billion in cash and aims for breakeven in 2028. The stock surged 8.85% in premarket trading as the settlement value was better than investors' worst-case fears.Benzinga · Mar 4, 2026

Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands OutNeo Ivy Capital Management initiated a new position in American Healthcare REIT by purchasing 136,925 shares worth approximately $6.44 million. The REIT delivered strong 16.4% same-store NOI growth in Q3, driven by senior housing and integrated senior health campuses segments. Shares have surged 93% over the past year, with management raising full-year guidance.The Motley Fool · Feb 13, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025Immunovant reported Q3 2025 financial results with a net loss of $110.6 million. The company's IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis is fully enrolled with topline data expected in H2 2026. A $550 million financing was completed in December 2025, extending cash runway through potential Graves' disease launch. Development remains on track across multiple indications including GD, MG, CIDP, and SjD.GlobeNewswire Inc. · Feb 6, 2026

to start trading

RO

ROIVRoivant Sciences Ltd. Common Shares

ROIV

Pay with—

Available Balance0.00

Your PositionYou don't own any ROIV yet.

Related Tickers

Earnings